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Abstract
Background—Sex differences among adults in healthcare treatment and outcomes have been 
reported, however, there is a paucity of literature regarding pediatric populations, particularly 
adolescents with Crohn’s disease (CD). The objective was to identify whether sex differences 
exist with respect to complications, procedures, and medication usage (corticosteroids, biologic 
agents, and total parenteral nutrition (TPN)) among hospitalized adolescents with CD.
Methods—Adolescents with CD (n=5782) hospitalized between April 1, 2004–June 30, 2012 
were selected from the Pediatric Health Information System database with a 1:1 ratio of males to 
females by hospital. Frequency of disease complications, associated conditions, procedures 
performed, and medication usage were analyzed with non-parametric statistical tests for the 
existence of sex differences.
Results—5782 patients were included with a median age of 15 years. Females were slightly 
more likely to have anemia (29% vs. 25%, p=0.012), infection (12% vs. 8%, p=0.001), and mood 
disorder (9% vs. 6%, p<0.001), whereas males had more maturational delays (3% vs. 1%, 
p=0.004), and malnutrition (18% vs. 14%, p=0.027). Among procedures, only one category 
demonstrated a sex difference: females had more blood product transfusions (9% vs. 6%, 
p<0.001). Female rates for corticosteroids (62%), biologic agents (16%) and TPN (18%) were not 
statistically different from those for males (62%, 15%, and 20%, respectively). There were no 
differences in length of stay by sex.
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Conclusions—This cross-sectional study of an administrative database identified few sex 
differences among adolescents with CD. The effect sizes were universally small and generally 
consistent with known sex differences unrelated to IBD.
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Introduction
Understanding sex differences in disease symptoms and response to treatment may be an 
important pathway for understanding disease etiology, treatment and improving overall 
care1, 2. Investigations into sex differences have alerted providers in diverse fields to 
potential biases in diagnosis and treatment2–4 and suggested changes to traditional 
practice.5–7. While sex differences in prevalence, treatment, and patient outcomes have been 
identified and studied among adults(e.g., depression, cardiovascular, and autoimmune 
diseases1, 8–13), much less is known concerning such differences in pediatric populations, 
particularly for Crohn’s disease (CD), a chronic, relapsing, autoimmune disease.
Consistent evidence for sex differences in the treatment, course and outcomes of both adult 
and pediatric patients with CD is lacking. A large retrospective cohort analysis of adults in 
the Kaiser Permanente Inflammatory Bowel Disease registry found no differences in the risk 
for rehospitalization or colectomy.14 In other adult cohort studies, females were more likely 
to have extraintestinal manifestations (EIMs, such as arthritis, erythema nodosum, and 
ocular manifestations),15, 16 while males had higher disease remission rates17 but a greater 
decline in bone mineral density compared with non-CD controls.18, 19
Prior studies in children are conflicting: demonstrating either greater severity in males, 
greater severity in girls, or finding no sex differences. For example, males appear to be at a 
higher risk than females for growth failure.20–22 In contrast, females may be more likely to 
have hypoalbuminemia and mouth sores at diagnosis, and generally have a more severe 
disease course.20 In a study assessing risk factors for intestinal resection surgery, females 
were at greater risk compared to males.23 Several studies have reported no sex differences 
with respect to patient symptoms or EIMs,24 risk of intestinal resection surgery,23, 25, 26 or 
in disease severity, BMI, height velocity, or medication use.27
Given the conflicting evidence among mostly small-scale studies in the pediatric CD 
literature, the present study sought to address this gap by using a large administrative 
database with diagnostic and treatment data across multiple, geographically diverse 
children’s hospitals to evaluate a cross-section of hospitalized, male and female adolescent 
patients with respect to medical management, complications, and procedures. If sex plays a 
significant role in Crohn’s etiology and outcomes, this effect may be pronounced during 
puberty. Further, as adolescence is a period of peak onset of CD, it may be an optimal time 
to assess potential sex differences. The main objective of the present study was to identify 
whether sex differences exist with respect to complications, procedures, and medication 
usage (corticosteroids, biologic agents and total parenteral nutrition (TPN)) among 
hospitalized adolescent patients with CD.
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The Pediatric Health Information System (PHIS) is an administrative database established 
and maintained by the Children’s Hospital Association (CHA) on behalf of its 44 affiliated 
children’s hospitals which comprise approximately 25% of pediatric centers in the United 
States. Data (e.g. demographics, diagnoses, procedures, and medications) are collected in 
standardized formats for each hospitalized patient. Reliability and validity are assured by 
each hospital and by CHA before database inclusion. For this study period, data from 44 
hospitals were available and all 44 hospitals were included.
Study Design
This was a cross-sectional study of male and female adolescent patients who were 
hospitalized with a diagnosis of CD. This study was approved by the Nationwide Children’s 
Hospital Institutional Review Board.
Study Cohort
The study population was derived from adolescent patients (age 13 to 18 years) identified in 
the PHIS database by a primary or secondary diagnosis of Crohn’s disease (ICD-9: 555.x) 
during their first (index) hospital admission within the study time period of January 1, 2004 
and June 30, 2012. This age range was selected as a simple way to encompass the majority 
of pubertal/growth changes for both sexes. To be included, patients had to have sex 
recorded, and no admissions in the preceding three months. Patients with admission dates 
within the first three months (January 1, 2004 to March 31, 2004) were excluded in order to 
increase the likelihood that their initial hospitalization occurring at the beginning of the 
study period was not a readmission related to a prior hospitalization. Although this study did 
not consider encounters outside of the initial hospitalization, patients were also excluded if 
there were inconsistencies in the reporting of sex or birthdate across encounters. This more 
conservative approach allowed us to reduce reporting errors. Specific hospitalizations were 
excluded if the encounter was for an ostomy take down (CPT 44625, ICD-9 procedure code 
46.5x) or if the encounter had the same admission and discharge date.
Subsequent to applying inclusion and exclusion criteria, a subset of male and female 
subjects was randomly selected to achieve a 1:1 ratio at the hospital level (Figure 1).
Measures
Demographic descriptors collected for each subject (distinguished by encrypted medical 
record number (MRN)) included sex, age, race, ethnicity, payor status, ZIP code 
(encrypted), median neighborhood income, and hospital location. Payor status was 
categorized into one of three groups: commercial insurance, Medicaid, or other (APPENDIX 
A). Individuals were initially assigned to one of 4 race categories: a specific race category 
(e.g., White, Black, Asian, if they consistently endorsed the same race across all 
encounters), “mixed race” (if they endorsed more than one race), “missing” (if race was 
consistently missing across encounters), or “inconsistent” (if there were any reporting 
discrepancies). For demographic analysis, race and ethnicity were defined as: non-Hispanic 
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White, non-Hispanic Black, non-Hispanic other (including Asian, Pacific Islander, 
American Indian, mixed-race, and other), and Hispanic.
Additional variables collected included admission and discharge dates, discharge ID, 
intensive care unit (ICU) admission flag, length of stay (LOS), and use of specific 
medications (corticosteroids, biologic agents and TPN). Median neighborhood income was 
derived by the PHIS data analytics team using the United States Census-based values 
corresponding to their actual ZIP codes. Regional divisions (Northeast, South, Midwest, and 
West) were derived from hospital location based on the 2010 Census Regions and Divisions 
of the United States (www.census.gov).
To assess the use of the most frequent procedures and surgical complications among all 
patients in the final study cohort, lists of the top 200 procedural codes and complication 
diagnoses codes were generated. From these two lists, procedural and complication/
associated diagnoses groups were constructed based on clinical relevance to CD. Compared 
to a simple search of specific ICD-9 codes, this approach was less likely to inadvertently 
overlook common procedural and diagnostic codes. (APPENDIX B)
Outcomes
The primary outcome measures included the presence of complications, procedure 
utilization, and medication utilization. The secondary outcome was LOS.
Analysis plan
The Mann-Whitney U test was used to identify sex differences on age at admission and 
median income. The Chi-square test for contingency tables was used to identify sex 
differences in the proportion of male versus female subjects on race/ethnicity and payor 
status, medications received, complications, and procedures performed. All tests were two-
sided. For each set of analyses, we assumed a critical alpha of 0.05 and made Bonferroni 
corrections for multiple testing where appropriate.
Effect sizes were calculated (e.g. phi (ϕ) for Chi-square contingency tables) to describe the 
magnitude of statistically significant sex differences. We considered an effect size greater 
than 0.15 to be clinically meaningful; although a small effect may not be apparent in 
individual practice, it is important from a population health perspective where small effects 
are magnified in the larger population of affected individuals. With 2891 males and 2891 
females, this study has at least 80% power to detect small effects using a X2 test with a 




Table 1 summarizes the demographics according to sex. By design (1:1 ratio of males to 
females within each hospital), there were no sex frequency differences by region.
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Female rates for corticosteroids (n = 1781, 62%), biologic agents (n = 460, 16%) and TPN 
usage (n = 509, 18%) were not statistically different from those for males (n = 1798, 62%, p 
= 1; n = 444, 15%, p = 1; and n = 570, 20%, p = 0.129 (adjusted based on Bonferroni 
correction), respectively).
Complications
Among the top 200 diagnoses reported, 75 were found to have clinical relevance to CD. The 
frequency of reported ICD-9 codes ranged from 0.4% for “Intestinal obstruction NOS” 
(ICD-9 code = 560.9; not otherwise specified (NOS)) to 11.1% for “Anemia NOS” (ICD-9 
code=285.9). There were sex differences in 4 of 19 diagnostic groups identified. Females 
were slightly more likely to have anemia (29% versus 25%, p = 0.012, ϕ = 0.04), infection 
(12% versus 8%, p = 0.001, ϕ = 0.05), and mood disorder (9% versus 6%, p < 0.001, ϕ = 
0.07), whereas males had more pubertal complications (such as delays in maturation, 
including short stature and sexual development; 3% versus 1%, p = 0.004, ϕ = 0.05), and 
more nutritional complications (including malnutrition and under nutrition, 18% versus 
14%, p = 0.027) (Table 2). With respect to greater infections among females, it should be 
noted that these were largely explained by urinary tract infections (UTIs); when UTIs were 
removed from the infection category in a post hoc analysis, the sex difference for the 
remaining infections as a group was diminished and no longer significant (10% female 
versus 8% males, X2 = 7.76, p = 0.102, ϕ = 0.04).
Procedures
Among 84 CD-related procedures identified, the frequency of ICD-9 codes ranged from 
0.1% for “Other laparoscopic partial excision of large intestine” (ICD-9 code = 17.39) to 
34.8% for “Closed [endoscopic] biopsy of large intestine” (ICD-9 code = 45.25). Of 13 
procedural categories (APPENDIX B), only one demonstrated a sex difference: females had 
more blood product transfusions compared to males (9% versus 6%, p=0.002, ϕ =0.05) 
(Table 3). There were no differences in LOS between males (mean = 6.5 ± 10.0, median = 4 
days) and females (mean = 6.5 ± 7.4, median = 4 days) (p = 0.280, d = 0.002).
Discussion
This study identified several small sex differences among CD related diagnoses and 
procedures, much of which is explained by known sex differences in the general population. 
The observed sex difference in anemia was expected given the increased prevalence of 
anemia in adolescent girls as compared to boys in the general population. The third National 
Health and Nutrition Examination Survey (NHANES III) found a prevalence for iron-
deficiency anemia of 2–5% among non-pregnant female adults (2–3% among adolescents) 
and 1–2% in male adults (< 1% among adolescents).28
Given that females have a higher baseline rate of anemia; it may not be surprising to have 
found a small difference in the rate of transfusions in our study. However, there are other 
sex related factors that may contribute to blood transfusions being more prevalent among 
adolescent females (9%) compared with males (6%). Androgens have a stimulating effect on 
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erythropoiesis,29 with lower androgen levels and therefore lower hemoglobin concentrations 
in adolescent females.30 Also, given the wide inter-hospital variation in thresholds for 
transfusion,31–33 such decisions are likely based on a combination of objective and 
subjective factors. Since females have been found to have a slightly greater tendency for 
self-disclosure,34 they may be more willing to communicate (and providers more likely to 
respond to35) subjective symptoms such as dizziness, headache, and fatigue, which may 
increase their likelihood for anemia-related transfusions in less severe cases. Finally, if 
females have a more severe disease course during initial hospitalization as previously 
suggested, a greater need for transfusion might be seen.20
As with anemia, we found sex differences for disorders involving depression as well as 
anxiety that may be explained by sex differences in the general population, with a higher 
prevalence of mood disorders among females.36 Sex-based differences in brain functioning 
as well as circulating gonadal steroids have different effects on cortisol response and 
hypothalamic-pituitary-adrenal axis reactivity. In addition to such biological differences, it 
has been speculated that the higher female incidence for depression and anxiety may reflect 
psychological differences, such as a differential response to stress from interpersonal life 
events.37–40 Similarly, although we found differences in rates of infections, this was no 
longer significant after removing UTIs, a condition known to be more common among 
females during adolescence in the general population.41
In contrast, the difference in abnormal growth and development in our study are not readily 
explained by differences in the general population, and are consistent with findings from 
previous research. Growth failure, delayed puberty, subnormal height velocity, and short 
stature are all commonly observed among adolescents with CD generally42–44. A previous 
study showed the risk for growth failure (height or height velocity at the fifth percentile) 
among girls was 0.28 times the risk in boys (p < 0.002) over a ten year follow-up, with a 
final cumulative incidence of 4.0% versus 12.6%.20 The rate of complications of growth and 
development in our study was lower than previously reported. We expected to observe a 
lower prevalence (under-reporting) of these conditions in our study cohort given that our 
study population was strictly an inpatient cohort. Growth, height velocity, and puberty are 
more likely to be clinically assessed, managed, and followed longitudinally, and thus more 
likely to be entered as diagnoses codes in an outpatient setting.
There were no sex differences among corticosteroid, biologic agent, or TPN usage. While no 
prior studies of CD medications in a hospitalized pediatric population were identified for 
comparison, there were three relevant studies of adult populations. Females were found to 
receive immunosuppressive medications less frequently,17 have lower cumulative 
corticosteroid use,18 and were slightly less likely to initiate infliximab infusions (non-
significant trend)45 compared with males. Our results were consistent, however, with a large 
outpatient IBD study which also found no sex differences in medication use.27 Perhaps some 
of the differences that were seen in adults could be explained by less disease severity among 
adult women, impact of disease duration, or effects of treatment decisions which occur 
during pregnancy or child-bearing years.
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There were several important limitations in the present study. We evaluated only the first 
index hospitalization for each patient, which does not address potential differences in 
outpatient management (not captured in PHIS) or in subsequent hospitalizations. We 
recognize that CD is mainly treated on an outpatient basis without hospitalization. The 
outpatient management and clinic visits are integral components in the management of 
adolescents with CD. Further, the PHIS database is not weighted for extrapolation to 
national estimates, thus results may not be generalizable to all pediatric centers. Also, this 
was a retrospective study based on administrative data, so reporting bias or classification 
errors may be present, although there are data quality measures in place to minimize errors. 
Since the findings were not based on detailed medical record review, we were unable to 
assess or control for disease phenotype, location or symptoms. Finally, while we believe that 
small observed differences are likely due to biological causes, we cannot rule out the 
possibility that they may also be due to other factors such as differential access to care, 
adherence, or treatment based on sex46, 47. The strengths of the study include its large 
sample size, regionally diverse population, and the focus on a hospitalized cohort with likely 
moderate to severe disease, thereby minimizing any confounding of severity with sex 
differences. We also focused on the adolescent population, which allowed us to better 
observe hormonal-based sex differences in a pediatric cohort.
In conclusion, this cross-sectional study of an administrative database identified few sex 
differences among adolescents with CD. The effect sizes were universally small and 
consistent with the expectations in the general population. Sex did not have a large effect on 
the outcomes assessed in this study.
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Flowchart for the final cohort selection process and exclusion criteria. After applying 
exclusion criteria to the initial database sample of patients age 13 to 18 years, and 
subsequently applying a 1:1 ratio of males to females within each hospital, the final study 
cohort was determined. MRN = medical record number.
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TABLE 1
Demographic Characteristics by Sex for a Hospitalized Adolescent Crohn’s Disease Cohort
Variable Femalen (%)
Male
n (%) P value
Total 2891 (50) 2891 (50) n/a
Race/Ethnicity
 Non-Hispanic White 2024 (70) 1936 (67) 0.194
 Non-Hispanic Black 475 (16) 512 (18)
 NH Other 173 (6) 204 (7)
 Hispanic 133 (5) 150 (5)
 Missing 57 (2) 63 (2)
 Inconsistent 29 (1) 26 (1)
Age, Median [Q1–Q3]1 15 [14–17] 15 [14–17] 0.081
Region2
 Midwest 857 (30) 857 (30) n/a
 Northeast 701 (24) 701 (24)
 South 946 (33) 946 (33)
 West 387 (13) 387 (13)
Payor3
 Commercial 1276 (44) 1255 (43) 0.592
 Medicaid 605 (21) 647 (22)
 Other 969 (34) 946 (33)








Median age represented with quartile ranges: Q1 and Q3 refer to the first (25%) and third (75%) quartiles
2
Region assignment: Midwest (OH, IL, MI, IN, MO, WI, MN, NE, ND, SD, KS, IA); Northeast (ME, NH, VT, NY, MA, CT, RI, PA, NJ); South 
(DC, MD, VA, DE, WV, KY, TN, NC, SC, GA, AL, MS, FL, LA, TX, AR, OK); West (AZ, CO, CA, WA, OR, MT, WY, ID, NV, UT, NM, HI, 
AK)
3
Payor status was collated into the following categories: Commercial=Blue Cross, HMO, TRICARE, Commercial HMO, Commercial PPO, 
Commercial Other; Medicaid=Medicaid, In-state Medicaid (managed care), In-state Medicaid (other), Out-of-state Medicaid (all); 
Other=Medicare, Title V, Other government, Workers Compensation, other insurance company, self-pay, no charge, other payor, charity, hospital 
chose not to bill; Missing=not recorded, invalid code, unknown
4
Median of median income based on 2010 US Census Data compared to ZIP code reported at index hospitalization
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TABLE 2
Crohn’s Disease Related Diagnoses at Index Hospitalization
Variable Total Femalen (%)
Male
n (%) P value
1
Anemia 1552 834 (29) 718 (25) 0.012
Nutrition complications 928 419 (14) 509 (18) 0.027
Dehydration/hypovolemia 599 313 (11) 286 (10) 1
Infection (others) 585 340 (12) 245 (8) 0.001
Obstruction 553 243 (8) 310 (11) 0.060
Perianal disease 473 207 (7) 266 (9) 0.102
Mood Disorders 439 270 (9) 169 (6) <0.001
EIM 383 185 (6) 198 (7) 1
Intra-abdominal abscess 326 149 (5) 177 (6) 1
Electrolyte anomalies 220 111 (4) 109 (4) 1
Other 213 104 (4) 109 (4) 1
Fistula 167 79 (3) 88 (3) 1
Irritable Bowel Syndrome 154 90 (3) 64 (2) 0.760
C. difficile infection 145 72 (2) 73 (3) 1
Perforation/peritonitis 115 57 (2) 58 (2) 1
Pubertal complications 112 36 (1) 76 (3) 0.004
Autoimmune 63 42 (1) 21 (1) 0.190
Bacteremia/sepsis 48 29 (1) 19 (1) 1
Vitamin D deficiency 43 19 (1) 24 (1) 1
1
Bonferroni corrected p-values
Total cohort n=5782 (Female=2891 and Male=2891)
Bolded p values represent significant findings
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TABLE 3
Crohn’s Disease Related Procedures at Index Hospitalization
Variable Total Femalen (%)
Male
n (%) P value
1
Endoscopies 2241 1116 (39) 1125 (39) 1
Colectomy 436 211 (7) 225 (8) 1
Blood product transfusions 426 251 (9) 175 (6) 0.002
Resection/anastomosis 227 97 (3) 130 (4) 0.390
Abdominal surgery 219 105 (4) 114 (4) 1
Wound/lesion related 184 87 (3) 97 (3) 1
Perianal/perineal procedures 181 80 (3) 101 (3) 1
Appendectomy 145 67 (2) 78 (3) 1
Ostomy 110 54 (2) 56 (2) 1
Central access 95 40 (1) 55 (2) 1
Other 55 32 (1) 23 (1) 1
Intra-abdominal fistula repair 25 11 (0) 14 (0) 1
Cholecystectomy 12 7 (0) 5 (0) 1
1
Bonferroni corrected p-values
Total cohort n=5782 (Female=2891 and Male=2891)
Bolded p values represent significant findings
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